Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHC 2023 | Outcome measures for migraine medication trials in children

Prab Prabhakar, MBBS, FRCPCH, Great Ormond Street Hospital (GOSH) NHS Foundation Trust, London, UK, addresses the need to develop effective outcome measures to assess the efficacy of migraine medication in children. Traditionally, reported pain ratings and the Pediatric Migraine Disability Assessment (PedMIDAS) have been used. Placebo response rates are high in pediatric migraine trials, as evidenced in the recent triptan trials, so an absence of pain may not be the most reliable indicator of drug effectiveness. Dr Prabhakar suggests considering children’s participation in daily activities, particularly school, as an outcome measure. This interview took place during the 7th European Headache Congress (EHC) 2023.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.